Top biotech investor says Trump's criticism of Pfizer is scaring drug companies from raising prices

Sarissa's Alex Denner says President Trump’s criticism of pharmaceutical giant Pfizer is having an impact on how other companies in health care set their prices.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.